众生药业：与齐鲁制药签署RAY1225注射液许可协议，获2亿元首付款及最高8亿元里程碑付款

Core Viewpoint - Zhongsheng Pharmaceutical announced a licensing agreement with Qilu Pharmaceutical for the production and commercialization of RAY1225 injection in China, retaining global intellectual property rights and MAH status [1] Group 1 - Zhongsheng Ruichuang signed a licensing agreement with Qilu Pharmaceutical on January 16, 2026 [1] - The agreement includes an upfront payment of 200 million RMB and potential milestone payments up to 800 million RMB for development and sales [1] - Zhongsheng Ruichuang will also receive a double-digit percentage of net sales as royalties [1]